Bacterial Conjunctivitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Bacterial Conjunctivitis - Pipeline Review, H1 2016', provides an overview of the Bacterial Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis - The report reviews pipeline therapeutics for Bacterial Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bacterial Conjunctivitis therapeutics and enlists all their major and minor projects - The report assesses Bacterial Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bacterial Conjunctivitis Overview 6 Therapeutics Development 7 Pipeline Products for Bacterial Conjunctivitis - Overview 7 Bacterial Conjunctivitis - Therapeutics under Development by Companies 8 Bacterial Conjunctivitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Bacterial Conjunctivitis - Products under Development by Companies 12 Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 13 Cellceutix Corporation 13 Daiichi Sankyo Company, Limited 14 InSite Vision Incorporated 15 NovaBay Pharmaceuticals, Inc. 16 Ocular Therapeutix, Inc. 17 Senju Pharmaceutical Co., Ltd. 18 Shire Plc 19 Bacterial Conjunctivitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 auriclosene - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 azithromycin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 azithromycin - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 brilacidin tetrahydrochloride - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ISV-405 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 levofloxacin - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 moxifloxacin hydrochloride SR - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SHP-640 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 vancomycin hydrochloride - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Bacterial Conjunctivitis - Recent Pipeline Updates 40 Bacterial Conjunctivitis - Dormant Projects 55 Bacterial Conjunctivitis - Product Development Milestones 56 Featured News & Press Releases 56 Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses 56 Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical 57 Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 57 Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 57 Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 58 Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma 58 Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco 58 Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 59 Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 59 Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for Bacterial Conjunctivitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Bacterial Conjunctivitis - Pipeline by Cellceutix Corporation, H1 2016 13 Bacterial Conjunctivitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 14 Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H1 2016 15 Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 16 Bacterial Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2016 17 Bacterial Conjunctivitis - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 18 Bacterial Conjunctivitis - Pipeline by Shire Plc, H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 27 Bacterial Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2016 40 Bacterial Conjunctivitis - Dormant Projects, H1 2016 55
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.